Medicenna Therapeutics Corp. announced the formation of its Clinical Advisory Board (CAB) comprised of Drs Paolo Ascierto, Lillian Siu and Hussein Tawbi. Medicenna's clinical advisory board is comprised of: Paolo A. Ascierto, M.D. is a expert and key opinion leader in Immunotherapy.

Professor Ascierto is currently Director of the Department of Melanoma, Cancer Immunotherapy, and Development Therapeutics at the National Tumour Institute Fondazione G. Pascale, in Naples, Italy. His major research interests have included immunotherapy and vaccination treatments of solid tumors, combination strategies with immuno-oncology therapies, biochemical and immunological monitoring and assessment of new molecular markers for tumor progression. Lillian L Siu, M.D., FRCPC is a Professor of Medicine at the University of Toronto and a Senior Medical Oncologist at the Princess Margaret Cancer Centre where she serves as the Director of the Phase I Program, Co-Director of the Bras and Family Drug Development Program, BMO Chair in Precision Genomics, and Director the Tumor Immunotherapy Program.

Her major research focus is in the area of new anti-cancer drug development, particularly with respect to Phase 1 trials and head and neck malignancies and has been leading genomics initiatives and immuno-oncology trials. Previously, Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Hussein A. Tawbi, M.D., Ph.D. is a leader in immunotherapy drug development.

He holds several appointments at The University of Texas MD Anderson Cancer Center's Department of Melanoma Medical Oncology, including as Professor, Deputy Chair, Director of Melanoma Clinical Research and Early Drug Development, and Director of Personalized Cancer Therapy. He is also a co-founder and Co-Director of the MD Anderson Brain Metastasis Clinic. Medicenna also announced that Dr. Kevin Moulder has left his position as Chief Scientific Officer to pursue another opportunity.